Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
Total Ratings | 5 | 4 | 3 | 0 | 1 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 1 | 2 | 0 | 0 |
2M Ago | 2 | 1 | 1 | 0 | 0 |
3M Ago | 2 | 2 | 0 | 0 | 1 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $455.69, a high estimate of $550.00, and a low estimate of $371.00. Surpassing the previous average price target of $444.82, the current average has increased by 2.44%.
Investigating Analyst Ratings: An Elaborate Study
The standing of Vertex Pharmaceuticals among financial experts...
